🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Implementing Polygenic Risk Scores for Breast Cancer Prevention: a Feasibility Study

RecruitingNAAges 18 Years - 79 YearsFemaleCatholic University of the Sacred Heart
NCT06922708 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This single-arm interventional feasibility study will evaluate whether integrating polygenic risk scores (PRS) into the CanRisk model can improve breast cancer risk prediction and personalized prevention in women at risk of breast cancer. The study will assess the organizational feasibility, patient acceptance, emotional impact and satisfaction of an integrated pathway combining PRS testing with standard genetic counseling and other risk factors at Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Ability to provide informed consent * Voluntary consent to participate * Estimated risk of carrying an inherited pathogenic variant (in BRCA1, BRCA2, PALB2, CHEK2, ATM, RAD51D, RAD51C, BARD1) \> 5%, (calculated on www.canrisk.org) * Healthy women with: 1. Known family history of breast cancer, or 2. Known familiarity with carriers of pathogenic variants for genes included in the CanRisk model (BRCA1, BRCA2, PALB2, CHEK2, ATM, RAD51D, RAD51C, BARD1), or 3. Known carriers of pathogenic variants for genes included in the CanRisk model (BRCA1, BRCA2, PALB2, CHEK2, ATM, RAD51D, RAD51C, BARD1) * Affected women with: 1. Diagnosis of unilateral breast cancer 2. Personal history of ovarian cancer Exclusion Criteria: * Diagnosis or history of bilateral breast cancer * Diagnosis of ductal carcinoma in situ * Previous bilateral mastectomy * Life expectancy \< 12 months due to other medical conditions * Participation in interventional clinical trials for breast cancer prevention in the last 12 months * Carriers or relatives of carriers of pathogenic variants in genes not included in the CanRisk model (genes other than BRCA1, BRCA2, PALB2, CHEK2, ATM, RAD51D, RAD51C, BARD1) * Inability to provide informed consent
💊

What it tests

  • Clinical pathway for breast cancer prevention based on PRS-integrated CanRisk assessment
📍

Where

1 site
Policlinico Universitario Fondazione Agostino Gemelli
Roma, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy